A Phase IV Open-label, Multicentre, International Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir ±Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection and Recent Injection Drug Use or Receiving Opioid Substitution Therapy

Trial Profile

A Phase IV Open-label, Multicentre, International Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir ±Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection and Recent Injection Drug Use or Receiving Opioid Substitution Therapy

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Dasabuvir; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms D3FEAT
  • Most Recent Events

    • 08 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 29 Aug 2016 Status changed from not yet recruiting to recruiting.
    • 17 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top